The suppressed production of platelets (e.g., reduced TPO expression and bone marrow suppression by hepatitis virus infection and anticancer agents) and increased consumption and destruction of platelets (e.g., splenic sequestration and coagulopathy) are generally believed to be major responses contributing to the development of thrombocytopenia in patients with liver disease5–9. Here, TPO is linked to Thrombocytopenia.